Mouse Monoclonal KDM1A Antibody

The KDM1A antibody is a crucial tool in epigenetic research, targeting the lysine-specific histone demethylase 1A (KDM1A/LSD1), an enzyme pivotal in regulating gene expression. KDM1A, a member of the flavin-dependent amine oxidase family, removes methyl groups from mono- or dimethylated histone H3 at lysine 4 (H3K4me1/2), repressing transcription. It interacts with corepressor complexes like CoREST, influencing cellular processes such as differentiation, proliferation, and apoptosis. Dysregulation of KDM1A is linked to cancers (e.g., leukemia, breast cancer), neurological disorders (e.g., Alzheimer’s), and other diseases, making it a potential therapeutic target. KDM1A antibodies enable detection and quantification of the protein in techniques like Western blotting, immunohistochemistry, and ChIP-seq, aiding studies on its expression, localization, and functional roles. They also support drug development by validating KDM1A inhibitors in preclinical models. As research advances, these antibodies remain vital for unraveling KDM1A's complex regulatory networks and its implications in disease mechanisms, highlighting their dual role as both research tools and assets in therapeutic innovation.